Clinical Trial: A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Study Status: Completed
Recruit Status: RECRUITING
Condition: Endometrioid Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)
Brief Summary:
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or cervical cancer.
Read more